



ONCOTECH SUPPORTIVE ABSTRACTS & STUDIES





EXTREME DRUG RESISTANCE (EDR®) ASSAY SUPPORTIVE LITERATURE

ARTICLES

d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, Yu I-R, Luketich D

Chemotherapy resistance and oncogene expression in non-small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery 2007; 133(2): 352-63.

Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R

In Vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas

Clin Cancer Res 2006; 12(15): 4523-4532.

d'Amato TA, Landreneau RJ, McKenna RJ, Santos, RS, Parker RJ

Prevalence of In Vitro Extreme Chemotherapy Resistance in Resected Non-small-Cell Lung Cancer

Annals of Thoracic Surgery, 2006, 81(2): 440-447.

Tewari D, Monk BJ, Al-Ghazi MS, Parker R, Heck JD, Burger RA, Fruehauf JP

Gene Expression Profiling of In Vitro Radiation Resistance in Cervical Carcinoma: A Feasibility Study

Gynecologic Oncology, 2005, 99: 84-91.

Tewari KS, Mehta RS, Burger RA, Yu IR, Kyshtoobayeva AS, Monk BJ, Manetta A, Berman ML, Disaia PJ, Fruehauf JP

Conservation of In Vitro Drug Resistance Patterns in Epithelial Ovarian Carcinoma

Gynecologic Oncology, 2005, 98: 360-368.

Alberts DS, Fruehauf JP

In Vitro Drug Resistance Versus Chemosensitivity: Two Sides of Different Coins

Journal of Clinical Oncology, 2005, 23: 3641-3643.

Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP

In Vitro Chemosensitivity and Biomarker Profiles Are Unique for Histologic Subtypes of Epithelial Ovarian Cancer

Gynecologic Oncology, 2004, 92: 160-166.

Parker RJ, Fruehauf JP, Mehta RS, Filka E, Cloughesy T

Prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma

Journal of Neuro-Oncology, 2004, 66: 365-375.

Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML

Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy

American Journal of Obstetrics and Gynecology, 2003, 189:5, 1301-1307.

Holloway RW, Mehta RS, Finkler NJ, Li K-T, McLaren C, Parker RJ, Fruehauf, JP

Association between in Vitro Platinum Resistance in the EDR Assay and Clinical Outcomes for Ovarian Cancer Patients

Gynecologic Oncology, 2002, 87:1, 8-16.

Monk BJ, Burger RA, Parker RP, Radany EH, Redpath L, Fruehauf JP

Development of an in Vitro Chemo-Radiation Response Assay for Cervical Carcinoma

Gynecologic Oncology, 2002, 87:2, 193-199.

Fruehauf JP

In vitro assay-assisted treatment selection for women with breast or ovarian cancer

Endocrine-Related Cancer, 2002, 9: 171-182.

Haroun RI, Clatterbuck RE, Gibbons MC, Burger PC, Parker RJ, Fruehauf JP, Brem H

Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens

Journal of Neuro-Oncology, 2002, 58: 115-123.



EXTREME DRUG RESISTANCE (EDR®) ASSAY SUPPORTIVE LITERATURE

ARTICLES

Ellis RJ, Fabian CJ, Kimler BF, Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, Modrell C, Praeger M, McGinness M, Mehta R, Fruehauf JP

Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens Breast Cancer Research and Treatment, 2002, 71: 95-102.

Mehta RS, Bornstein R, Yu I-R, Parker RJ, McLaren CE, Nguyen KP, Li K-T, Fruehauf JP

Breast cancer survival and in vitro tumor response in the extreme drug resistance assay Breast Cancer Research and Treatment, 2001, 66: 225-237.

Devita VT and Chu E

Principles of Cancer Management: Chemotherapy

Principles and Practices of Oncology, Sixth Edition. 2001, Chapter 17.

Orr JW, Orr P, Kern DH

Cost-Effective Treatment of Women with Advanced Ovarian Cancer by Cytoreductive Surgery and Chemotherapy Directed by an In Vitro Assay for Drug Resistance

The Cancer Journal, 1999, 5(3).

Kern, DH

Heterogeneity of Drug Resistance in Human Breast and Ovarian Cancers

The Cancer Journal, 1998, 4(1).

a. Alberts. Commentary. Tumor Heterogeneity and Extreme Drug Resistance: Meet Your Match! The Cancer Journal, 1998, 4(1).

Brown E and Markman M

Tumor Chemosensitivity and Chemoresistance Assays

Cancer, 1996, 77: 1020-25.

a. Kern. Correspondence Cancer, 1997, 79(7): 1447-1449.

b. Markman. Correspondence: Author Reply. Cancer, 1997, 79(7): 1449-1450.

Fruehauf JP and Manetta A

Use of Extreme Drug Resistance Assay to Evaluate Mechanisms of Resistance in Ovarian Cancer: Taxol Resistance & MDR-1 Expression

Contributions to Gynecology and Obstetrics, 1994, 19:39-52.

Fruehauf JP and Bosanquet AG

In Vitro Determination of Drug Response: A Discussion of Clinical Applications

PPO Update, 1993(12).

Kern DH and Weisenthal LM

Highly Specific Prediction of Antineoplastic Drug Resistance With an In Vitro Assay Using Suprapharmacologic Drug Exposures

JNCI, 1990, 82(7): 582-588.



EXTREME DRUG RESISTANCE (EDR®) ASSAY SUPPORTIVE LITERATURE

ABSTRACTS

Zakashansky K, Bradley WH, Dottino P, Kolev V, Nagarsheth NP, Nezhat FR, Chuang L, Gretz H, Rahaman J

In Vitro Platinum Resistance in the Extreme Drug Resistance (EDR) Assay as a Predictor of Progression Free Interval in Primary Advanced Stage Ovarian Cancer

SGO 2008.

Yu I-R, Parker R, Mechetner E

In Vitro Testing of Drug Cross-Resistance to Improve Standard Combination Chemotherapy Selection in Colorectal Cancer

American Society of Colon and Rectal Surgeons 2007.

Yu I-R, Parker R, Mechetner E

In Vitro resistance profiles & biomarker expression in 414 freshly resected esophageal cancer specimens

SSO 2007.

Danovich S, Neofitos T, Fox S, Andaz S

Should Empiric Platinum-Based Chemotherapy be the Accepted Standard of Care in Surgically Resected Early Lung Cancer?

International Early Lung Cancer Action Program (IELCAP) Meeting at Cornell Medical Center, 2007.

Zakashansky K, Dottino P, Gretz H, Rosner M, Nagarsheth N, Nexhat F, Rahaman J

In Vitro Platinum Resistance in the Extreme Drug Resistance (EDR) Assay as a Predictor of Progression Free Interval in Primary Advanced Stage Ovarian Cancer

International Gynecologic Cancer Society 2006.

Panici PB, Testa U, Cognetti F, Angioli R, Bellati F, Mancini N, Petrucci E, Pasquini L, Palaia I, Perniola G, Basile S, Calcagno M, Di Donato V, Fruehauf JP, Yu IR, Peschle C

Extreme Drug Resistance Assay in Patients Affected by Cervical Cancer: Feasibility Results and Preliminary Chemotherapy Profile

International Gynecologic Cancer Society 2006.

D'Amato TA, Landreneau RJ, Huang WH, Parker R, Mechetner E, Yu I-R

Chemotherapy Resistance and Oncogene Expression in Non-Small Cell Lung Cancer

Western Thoracic Surgical Association 2006.

Yu I-R, Mechetner, E Huang WH

In Vitro Chemotherapy Drug Resistance Profiles in Colon Cancer: Analysis of 1,271 Cases of Colonic Adenocarcinoma

SSO 2006.

Huang WH, Yu I-R, Mechetner E

Association of DNA Ploidy and p53 Expression with 5-FU, CPT-11, and Oxaliplatin Resistance in the EDR Assay: A Study of 1,271 Colon Adenocarcinomas

ASCO GI 2006.

Santos RS, Patel AN, Gamblin CT, Fernando HC, Luketich JD, Landreneau RJ.

The Possible Role of Chemoresistance Testing in the Era of Post Surgical Adjuvant Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)

CHEST 2004.

Kerfoot CA, Thompson J, Richardson M, Pavich D, Ramsinghani SS, Goddard A, Eberhard DA

In Vitro Activity of Tarceva™ in Primary Lung and Colon Cancer Cells

Proc. American Association for Cancer Research, 2003.

ASCO 2002.

Fruehauf JP, Yu I-R, Parker R

In Vitro Drug Response and Biomarker Profiles for Ovarian Cancer Specimens Obtained at Initial Debulking or after Neoadjuvant Chemotherapy (EORTC 55971)

ASCO 2002.



EXTREME DRUG RESISTANCE (EDR®) ASSAY SUPPORTIVE LITERATURE

ABSTRACTS

Goodheart MJ, Rose S, Ritchie JM, Fruehauf JP, Deyoung BR, Buller RE

The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer
SGO 2002.

Tewari KS, Mehta RS, Yu I-R, Kyshtoobayeva AS, Manetta A, Fruehauf JP

In Vitro Drug Resistance Patterns in Epithelial Ovarian Cancer
SGO 2001.

Fruehauf JP, Mehta RS, Parker RJ, Burger R, Manetta A

Prospective Analysis of Association Between In Vitro Extreme Drug Resistance Assay Results and Clinical Outcomes for Ovarian Cancer Patients
ASCO 2001.

Fruehauf JP, Saha S, Mehta RS, Nora D, Singh T, Arora M, Wilson D, Metz J, Ng PS

Extreme Drug Resistance (EDR) Assay to Cisplatin (CP) and Survival in Ovarian Cancer Patients - A Comparative Analysis
ASCO 2000.

Fruehauf JP, Mehta RS, Parker RJ

Extreme Drug Resistance to Paclitaxel (T) In Vitro was Associated with Clinical Outcome in Metastatic Breast Cancer Patients Treated with T: A Multi-Institutional Prospective Blinded Trial
Proc. American Association for Cancer Research, 2000.

Gambino A, Favalli G, Salinaro F, Tognon G, Zanagnolo V, Pecorelli S

The Use of Extreme Drug Resistance Assay in Gynecological Malignancies after Failure of Conventional Chemotherapy
International Journal of Gynecological Cancer, Seventh Biennial Meeting of the International Gynecologic Cancer Society-Abstract. September, 1999, Rome, Italy.

Ellis RJ, Fabian CJ, Kimler BF, Fruehauf JP

Extreme Drug Resistance Testing in Primary Breast Cancer
ASCO 1999.

Yamada H, Kyshtoobayeva A, Yu I, Frantschy S, Fruehauf JP

In Vitro Drug Response in Histologic Subtypes of Ovarian Carcinoma
Proc. American Association for Cancer Research, 1999.



DiSC® ASSAY SUPPORTIVE LITERATURE

ARTICLES

Devita VT and Chu E

Principles of Cancer Management: Chemotherapy

Principles and Practices of Oncology, Sixth Edition. 2001, Chapter 17.

Bosanquet AG, Johnson SA, Richards SM

Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC Assay

British Journal of Haematology, 1999, 106: 71-77.

Bosanquet AG, Copplesstone JA, Johnson SA, Smith AG, Povey SJ, Orchard JA, Oscier DG

Response to cladribine in previously treated patients with chronic lymphocytic leukemia identified by ex vivo assessment of drug sensitivity by DiSC assay

British Journal of Haematology, 1999, 106(2):474-476.

Mason JM, Drummond MF, Bosanquet AG, Sheldon TA

The DiSC Assay: A Cost-effective Guide to Treatment for Chronic Lymphocytic Leukemia?

International Journal of Technology Assessment in Health Care, 15:1 (1999), 173-184.

Cortazar P, Gazdar AF, Woods E, Russell E, Steinberg SM, Williams J, Ihde DC, Johnson BE

Survival of Patients with Limited-Stage Small Cell Lung Cancer Treated with Individualized Chemotherapy Selected by in Vitro Drug Sensitivity Testing

Clinical Cancer Research, 1997, 3:741-747.

Bosanquet AG, Bell PB

Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rational for treatment strategies in chronic lymphocytic leukemia

Blood, 1996, 87(5): 1962-1971.

Fruehauf JP and Bosanquet AG

In Vitro Determination of Drug Response: A Discussion of Clinical Applications

PPO Update, Volume 7, 1993(12).

Weisenthal LM and Kern DH

Prediction of Drug Resistance in Cancer Chemotherapy: The Kern and DiSC Assays

Oncology, 1991, Vol. 5, No.9: 93-103.

Lathan B, Von Tettau M, Verpoort K, Diehl V

Pretherapeutic Drug Testing in Acute Leukemias for Prediction of Individual Prognosis

Haematology and Blood Transfusion Acute Leukemias II, 1990, Vol. 33: 295-298.

ABSTRACTS

Bosanquet AG, Bosanquet MI.

Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia

Leukemia, 2000, 14:712.

Bosanquet AG, McCann SR, Crotty GM, Mills MJ, Calovsky D

Methylprednisone in advanced chronic lymphocytic leukemia: Rationale for, and effectiveness of treatment suggested by DiSC assay

Acta Haematology, 1995, 93:73.

Wilbur DW, Camacho ES, Hilliard DA, Dill PL, Weisenthal LM

Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill

British Journal of Cancer, 1992, 65(1):27-32.



PROGNOSTIC & PREDICTIVE MARKERS ASSAY SUPPORTIVE LITERATURE

ARTICLES

Fine RL, Shah SS, Moulton TA, Yu I-R, Fogelman DR, Richardson M, Burris HA, Samuels BL, Assanasen C, Gorroochurn P, Hibshoosh H, Orjuela M, Garvin J, Goldman FD, Dubovsky D, Walterhouse D, Halligan G

Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy
Cancer Chemotherapy Pharmacol (2007) 59:429-437.

Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP

In Vitro Chemoresistance and Biomarker Profiles Are Unique for Histologic Subtypes of Epithelial Ovarian Cancer
Gynecologic Oncology, 2004, 92: 160-166.

Del Carmen MG, Smith Sehdev AE, Zahurak ML, Richardson M, Fruehauf JP, Montz FJ, Bristow RE

Endometriosis-Associated Ovarian Carcinoma- Differential Expression of Vascular Endothelial Growth Factor and Estrogen/Progesterone Receptors
Cancer 98 (8); 2003: 1658-1663.

Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E

Analysis of P-Glycoprotein - Mediated Membrane Transport in Human Peripheral Blood Lymphocytes Using the UIC2 Shift Assay
Cytometry Part A 53A: 67-78, 2003.

Reavey-Cantwell JF, Haroun RI, Zahurak M, Clatterbuck RE, Parker RJ, Mehta R, Fruehauf JP, Brem H

The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature
Journal of Neuro-Oncology 55: 195-204, 2001.

Mehta R, Kyshtoobayeva A, Kurosaki T, Small EJ, Kim H, Stroup R, McLaren CE, Li K-T, Fruehauf JP

Independent Association of Angiogenesis Index with Outcome in Prostate Cancer
Clinical Cancer Research, 2001 (7): 81-88.

Tewari KS, Kyshtoobayeva AS, Mehta RS, Yu I-R, Burger RA, Disaia PJ, Fruehauf JP

Biomarker Conservation in Primary and Metastatic Epithelial Ovarian Cancer
Gynecologic Oncology, 2000, (78): 130-136.

Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ

Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer
Journal of Clinical Oncology, 1999, 17(7): 1974-1982.

Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, MaKris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M

Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer
Journal of Clinical Oncology, 1999, 17(10), 3058-3063.

Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
Blood 1999, 94(6), 1840-1847.

Grant SW, Kyshtoobayeva A, Kurosaki T, Jakowatz J, Fruehauf JP

Mutant p53 Correlates with Reduced Expression of Thrombospondin-1, Increased Angiogenesis, and Metastatic Progression in Melanoma
Cancer Detection and Prevention, 1998 22(3): 185-194.

Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP

Levels of Multidrug Resistance (MDR1) P-Glycoprotein Expression by Human Breast Cancer Correlate with In Vitro Resistance to Taxol and Doxorubicin
Clinical Cancer Research, 1998, (4): 389-398.



PROGNOSTIC & PREDICTIVE MARKERS ASSAY SUPPORTIVE LITERATURE

ARTICLES

Fruehauf JP, Zonis S, Al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC

Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma

Chemico-Biological Interactions, 1998, 111-112; 277-305.

Fruehauf JP, Zonis S, Al-Bassam M, Kyshtoobayeva A, Dasgupta C, Milovanovic T, Parker RJ, Buzaid AC

Selective and Synergistic Activity of L-S, R-Buthionine Sulfoximine on Malignant Melanoma is Accompanied by Decreased Expression of Glutathione-S-Transferase

Pigment Cell Research, 1997, 10: 236-249.

Mechetner E, Schott B, Morse BS, Stein WD, Druley T, Davis KA, Tsuruo T, Roninson IB

P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity

Biochemistry, 1997, 94:12908-12913.

ABSTRACTS

Teoh D, Holloway R, Cohen J, Gu M, Ricketts W, Hu JM, Shin JY, Powell CB, Chen L, Chan JK

The association of ERCC1 and clinical outcomes of women with advanced ovarian cancer

Proc. American Society of Clinical Oncology, 2008.

Tawfik O, Peterson L, Parker R, Mechetner E, Davis M, Chapman J, Khan Q, Ma J

Correlation between immunohistochemical biomarker expression and in vitro drug response factors in stage III-IV ovarian cancer

Proc. American Society of Clinical Oncology, 2007.

Yu I-R, Parker R, Mechetner E

Biomarker expression profiles in primary verses metastatic colorectal tumors

Proc. American Association for Cancer Research, 2007.

Chan J, Shin J, Kapp D, Yu I-R, Parker R, Mechetner E

Biomarker and in vitro chemoresistance profiles of undifferentiated ovarian cancers

Proc. American Association for Cancer Research, 2007.

Yu I-R, Parker R, Mechetner E

In Vitro resistance profiles and biomarker expression in 414 freshly resected esophageal cancer specimens

SSO 2007.

Iddings DM, Koda EA, Grewal SS, Parker R, Saha S, Bilchik AJ

Mutant p53 Expression in Early Colorectal Cancer Corresponds with Reduced Expression of Thrombospondin-1 and Sentinel Node Metastases

5th International Sentinel Node Society Congress Meeting. Rome, Italy 2007.

Grewal S, Saha S, Patel M, Sehgal R, Parker R, Mechetner E, Yestrepky B, Wiese D, Yee C, Barber K

Angiogenesis index as a predictor of tumor burden in lymph nodes in colon cancer patients undergoing sentinel lymph node mapping

ASCO GI 2007.

Grewal S, Saha S, Patel M, Sehgal R, Parker R, Mechetner E, Wiese D, Arora M, Singh T, Barber K

Tumor marker analysis and sentinel lymph node mapping in colon cancer

ASCO GI 2007.

d'Amato TA, Landreneau RJ, Huang W, Parker R, Mechetner M, Yu I-R

Chemotherapy Resistance and Oncogene Expression in Non-Small Cell Lung Cancer

Western Thoracic Surgical Association, 2006.



PROGNOSTIC & PREDICTIVE MARKERS ASSAY SUPPORTIVE LITERATURE

ABSTRACTS

Yu I-R, Huang WH, Mechetner E

In Vitro Drug Resistance Profiles Correlate with DNA Ploidy and p53 Expression in 3,106 Endometrioid and Papillary Serous Adenocarcinomas of the Uterus

Proc. American Society of Clinical Oncology, 2006.

Huang WH, Yu I-R, Parker R, Mechetner E, d'Amato T, Landreneau R

In Vitro Drug Resistance in Non-Diploid and p53-Positive Non-Small Cell Lung Cancer: An EDR Study on 578 Freshly Resected Adenocarcinomas

Proc. American Society of Clinical Oncology, 2006.

Huang WH, Yen H, Hiroshima L, Bansil L, Yu I-R, Tee L

Morphological and Immunohistochemical Assessment of In Vitro Cell Proliferation of Fresh Human Tumor Tissues in an Agarose-Based Assay

Proc. American Association for Cancer Research, 2006.

Huang WH, Yu I-R, Mechetner E

Association of DNA Ploidy and p53 Expression with 5-FU, CPT-11, and Oxaliplatin Resistance in the EDR Assay: A Study of 1,271 Colon Adenocarcinomas

ASCO GI 2006.

Fruehauf JP, Tee L, Torres C, Dauffenbach L

Antiangiogenesis Activity of Buthionine Sulfoximine (BSO) Related to Glutathione Depletion and Dynein Overexpression

Proc. American Association for Cancer Research, 2004.

Fruehauf JP, Kyshtoobayeva A, Yu I-R

CD117/KIT Expression and Alkylator Resistance in Solid Tumors

Proc. American Association for Cancer Research, 2004.

Kerfoot C, Dauffenbach L, Huang W, Fruehauf JP

In Vitro Dosing Schedules in Breast and Ovarian Cancer and the Relationship with Topoisomerase I Expression

Proc. American Association for Cancer Research, 2004.

Leoni LM, Bailey B, Niemeyer CC, Reifert J, Bendall H, Dauffenbach L, Kerfoot C

In Vitro and Ex Vivo Activity of SDX-105 (Bendamustine) in Drug-Resistant Lymphoma Cells

Proc. American Association for Cancer Research, 2004.

Parker RJ, Haroun R, Clatterbuck R, Gibbons C, Brem H, Brem S, Sloane A, Barger G, Fruehauf J

Correlation of Tumor-Associated Biomarkers with In Vitro Drug Response (IVDR) in Malignant Gliomas

Proc. American Association for Cancer Research, 2003.

Shahbahrani B, Torres C, Huynh L, Fruehauf JP

Application of Surface-Enhanced Laser Desorption/Ionization Technology to Discover Ovarian Cancer Biomarkers for Early Detection and Individualized Treatment

Proc. American Association for Cancer Research, 2003.

Torres C, Fruehauf JP, Huynh L, Parker R

Enhanced Antimelanoma Activity After Exposure to BSO in Combination with Disulfiram

Proc. American Association for Cancer Research, 2003.

Torres C, Parker R, Fruehauf JP

Antiangiogenesis Effects of Docetaxel and L-Buthionine-S, R-Sulfoximine (BSO) on Tumor Derived Vascular Endothelial Cells

Proc. American Association for Cancer Research, 2002.



PROGNOSTIC & PREDICTIVE MARKERS ASSAY SUPPORTIVE LITERATURE

ABSTRACTS

Yamada H, Kyshtoobayeva A, Fruehauf JP

HER-2/neu and S-Phase in Breast Carcinoma

Proc. American Association for Cancer Research, 2000.

Wagner EA, Naab TJ, Parker RJ, Mehta RS, Tuckson W, McLaren CE, Nguyen K, Dawkins F, Kyshtoobayeva A, Fruehauf JP

Significant Association between Angiogenesis Index and Survival in Colorectal Cancer

Proc. American Association for Cancer Research, 2000.

Mechetner E, Tee L, Park SW, Fruehauf JP

High Throughput Screening for MDR1 Substrate Specificity Using the MDR1 Shift Assay

Proc. American Association for Cancer Research, 2000.

Mechetner E, Tee L, Fruehauf JP

The UIC2 Shift Assay Detects Functional P-glycoprotein in Tumors and Correlates with In Vitro Drug Response to Doxorubicin

Proc. American Association for Cancer Research, 90th Annual Meeting, 1999.



ONCOTECH GENOMIC RESEARCH STUDIES

microRNA Related Abstracts

Sokilde R, Hoiby PE, Smith DL, Ricketts W, Moller S, Lilman T

A new diagnostic platform for prediction of drug response based on a tumor's microRNA profile
Proc. American Association for Cancer Research, 2008.

Sokilde R, Hoiby PE, Nielsen BS, Rasmussen SV, Moller S, Ricketts W, Litman T

Global microRNA profiling using novel miRCURY LNA™ microarrays enables identification of tumor of unknown primary origin
Proc. American Association for Cancer Research, 2008.

ABSTRACTS

Zakashansky K, Bradley WH, Rahaman J, Dottino P, Ester C, Ricketts WA

Comparative Genomic Hybridization Predicts Time to Recurrence in Primary Ovarian Carcinoma
SGO 2008

d'Amato TA, Fernando HC, Chan BY, Ricketts WA, Luketich JD, Landreneau RJ

Differential Gene Expression Associated with Early Tumor Recurrence and Long Disease Free Survival in Early Stage Non-Small Cell Lung Cancer
SSO 2007.

Smith DL, Shahbahrami B, Covic S, Ricketts WA

Comparative Genomic Hybridization Screening Reveals Multiple DNA Amplifications that May be Predictive of Taxane Resistance
4th International Meeting on Cancer Molecular Markers, 2006

Covic S, Smith DL, Ricketts WA

Detecting Altered Expression and Activation of Signaling Pathways in Cisplatin Resistant Ovarian Cancer
Proc. American Association for Cancer Research, 2006

Re A and Ricketts WA

A 96-Well Soft Agar Based Assay for Testing Cell Lines and Tumors for Drug Resistance
Proc. American Association for Cancer Research, 2006

Smith DL, van Waes M, Ricketts WA

Correlating Signal Transduction Protein Kinase Levels, SNPs and Drug Resistance in Human Melanoma
Proc. American Association for Cancer Research, 2006

Smith DL, Shahbahrami B, Covic S, Ricketts WA

Identification of Amplifications and Deletions in Taxol Resistant Ovarian Cancer by Comparative Genomic Hybridization Screening
SGO 2006.

Smith DL, van Waes M, Ricketts WA

Optimization of protocols and screening of Topoisomerase II? for SNPs that predict response to etoposide and doxorubicin
Proc. American Association for Cancer Research, 2005.

Dauffenbach L, Torres C, Fruehauf J

Endothelial Cells Co-Cultured with Breast or Ovarian Cancer Demonstrated Differential Gene Expression and Apoptotic Response to Anti-Angiogenesis Therapy
Proc. American Association for Cancer Research, 2003.

Fruehauf JP, Dauffenbach L, Torres C, Petka M

Distinct Intrinsic and Dynamic Gene Expression Profiles Associated with Taxane Response in Breast and Ovarian Cancer
Proc. American Association for Cancer Research, 2003.

Fruehauf JP, Kyshtoobayeva A, Yu I-R, Pavich D, Torres C, McGann K, Chan B, Petka M, Pang P, Kiesner FJ

Differential Gene Expression Analysis Genetically Fingerprints Tumors of Unknown Primary
Proc. American Association for Cancer Research, 2002.